Search results
Results from the WOW.Com Content Network
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
Kiril Bratanov (1911-1986), pioneer in the area of immunology of reproduction; William Coley (1862-1936), pioneer of cancer immunotherapy; Albert Coons (1912-1978), developed immunofluorescent techniques for labelling antibodies; Max D. Cooper (1933-), identification of T and B cells; Yehuda Danon (1940-) Deborah Doniach (1912-2004), organ ...
William Bradley Coley (January 12, 1862 – April 16, 1936) was an American bone surgeon and cancer researcher best known for his early contributions to the study of cancer immunotherapy, specifically causing infection as a way to fight cancer, a practice used as far back as 1550 BC. [1]
Coley's toxins (also called Coley's toxin, [1] Coley's vaccine, [2] Coley vaccine, Coley's fluid or mixed bacterial vaccine) is a mixture containing toxins filtered from killed bacteria of species Streptococcus pyogenes and Serratia marcescens, named after William Coley, a surgical oncologist at the Hospital for Special Surgery who developed the mixture in the late 19th century as a treatment ...
The Breakthrough is written for the lay reader and includes sections on immunology that have been written for a general audience. It examines the development of cancer immunotherapy, starting with William Coley's work with toxins in the 1890s, moving on to the long hiatus of immunotherapy, and concluding with victory for the believers in the form of regulatory approval of CTLA-4, PD-1, and PD ...
Jimmy Carter is celebrating his historic 100th birthday.. The former president — who holds the record for the nation's longest-lived president — has spent 19 months in hospice care but has ...
In September 2014, a new cancer immunotherapy for melanoma patients called Keytruda became the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States. Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt, was one of the lead investigators of the clinical trial ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!